Second-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma. An open, multi-centric Study for Assessing the Safety of a Fixed-Dose Combination Therapy with Durvalumab plus Tremelimumab or Monotherapy with Durvalumab for treat-MedSci.cn

Second-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma. An open, multi-centric Study for Assessing the Safety of a Fixed-Dose Combination Therapy with Durvalumab plus Tremelimumab or Monotherapy with Durvalumab for treat

Rexer, H; Merseburger, A; Grohe, C

Rexer, H (reprint author), AUO Geschaftsstelle, Schwarz, Germany.

UROLOGE, 2018; 57 (3): 374

科室
- - 订阅+
  - 更多科室
工具
服务